Martin M. Coyne
Over the last 17 years, Marty has served as a board director, advisor and governance evaluator for a diverse group of public, private, family owned and early stage companies. Over this span, he has served in all board leadership positions including board chair, lead independent director and chair of the audit, compensation and governance committees.
As an operating executive at Kodak, he served as Executive Vice President and in numerous roles including Group Executive of the Photography Group, President of the Health Imaging and President of the Commercial businesses. Prior to that he served in leadership roles at Sterling Drug.
He is CEO and Chairman of the New Jersey Chapter of the National Association of Corporate Directors, is a NACD Leadership Fellow and a NACD Faculty member. In 2011, he was the recipient of the Directorship 100 Award. In 2013, Agenda Weekly named him a Top 50 Digital Director. He is a member of the Content Advisory Council for Tone at the Top for the Institute of Internal Auditors.
He is a frequent speaker, panelist and the author of numerous articles on leadership development, change management, strategy, innovation and corporate governance. He conducts and facilitates board evaluations and director assessments and mentors a select group of CEOs and directors. His book, How To Manage Your Board While Your Board Manages You, helps directors, CEOs and other C-Suite executives improve governance and the relationship between management and their board. He is also the Chairman and Founder of the CEO Learning Network.
Uday B. Kompella, PhD
Co-founder and Director
Dr. Kompella is an Ocugen Co-founder and a member of the board. He is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at University of Colorado-Anschutz Medical Campus, with research interests in the areas of drug discovery, drug delivery, and nanotechnology for treating a variety of degenerative, neovascular, and inflammatory disorders including retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, and cancers. Dr. Kompella is a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the Association for Research in Vision and Ophthalmology (ARVO) and serves as the Editor-in-Chief for the journal Expert Opinion on Drug Delivery. Also, he is an editor for the journals, Pharmaceutical Research and the Journal of Ocular Pharmacology and Therapeutics. Dr. Kompella is a recipient of the Distinguished Scientist Award (University of Nebraska Medical Center), Distinguished Teacher Award (University of Nebraska Medical Center), and Dean’s Mentoring Award (University of Colorado Anschutz Medical Campus). He is also a recipient of the ARVO Foundation for Eye Research/Pfizer Ophthalmics/Carl Camras Translational Research Award in Ophthalmology. Dr. Kompella obtained his PhD in Pharmaceutical Sciences from the University of Southern California.
Frank N. Leo
Mr. Leo is a consultant specializing in the pharmaceutical industry and private equity with over 30 years of experience in healthcare and pharmaceuticals. From 1999 to 2004, Mr. Leo served as President and Group President of Sterile Technologies and Life Sciences at Cardinal Health. He joined Cardinal Health following its acquisition of the sterile pharmaceutical contract manufacturing company Automatic Liquid Packing (ALP), where he held various senior level positions including Chief Operating Officer during his 16-year career. At Cardinal Health he oversaw the growth of the biotechnology and life sciences group, which was later spun out to form Catalent Inc. Mr. Leo left Cardinal Health in 2004, but continued to serve as a retained advisor through 2005. Mr. Leo then joined Morton Grove Pharmaceuticals where he served as CEO from 2006 to 2007, overseeing its sale for its Private Equity owners in 2007. Mr. Leo served as a Board Member of Rx Elite, Monogen, GeneraMedix, and Iogenetics and Capsugel. Mr. Leo is a serial entrepreneur having been involved in business value creation and start-ups in the Sterile Drug, Biotechnology and Healthcare technology spaces.
Shankar Musunuri, PhD, MBA
Chairman of the Board, CEO and Co-founder
Dr. Musunuri is a seasoned biotech veteran with more than 25 years of results-driven experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, Dr. Musunuri held leadership roles at numerous companies ranging from "Big Pharma" to novel start-up biotechs. Most recently, he founded Nuron Biotech, Inc., which he grew to a commercial company in less than three years, serving as President and CEO. Dr. Musunuri spent nearly fifteen years at Pfizer, where he gained extensive product launch and life-cycle management experience, playing a key role as Global Operations Team Leader for the most successful launch in vaccine history, Prevnar 13®. Prior to Pfizer, he was a group leader focused on Phase 3 clinical development at Amylin Pharmaceuticals.
Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut and an MBA from Duke University’s Fuqua School of Business. He is a recipient of the Distinguished Alumnus Award from the University of Connecticut’s School of Pharmacy and serves on the Advisory Board of Fuqua’s Center for Entrepreneurship and Innovation at Duke University.
Manish is Co-Founder and President of Innogenix Pharma, a generic pharmaceutical R&D and manufacturing company focused on solid oral dosage formulations, based in Long Island, New York.
He was previously Director of Business Development at Epic Pharma, a generic pharmaceutical company and CMO. While at Epic Pharma, he lead the M&A sale process in which the company was sold to Humanwell Healthcare of China in 2016.
Manish is actively involved in venture capital investing, in his capacity as CIO for a multi-family office. Areas of investment focus include: Generic pharmaceutical injectables, ophthalmic, topical, liquid, nasal, and solid oral dosage forms; Biotech from startup to public equity; and medical devices.
Prior to his experience in pharmaceuticals, Manish spent several years in finance as an analyst and trader, working in investment banking and hedge funds. He has experience investing across a variety of asset classes and strategies.
Manish holds a Bachelors of Science in Cellular and Molecular Biology from The Johns Hopkins University and a Masters Degree in Financial Engineering from New York University.
Suha Taspolatoglu, MD
Dr. Taspolatoglu is the chief executive officer of the 105 year old Abdi Ibrahim Ilac Sanayi ve Ticaret A.S., a market leader of the pharmaceutical sector in Turkey for nearly two decades. Dr. Taspolatoglu joined Abdi Ibrahim as the head of sales and marketing division in 2001 and became managing director of sales and marketing division six short years later. Prior to Abdi Ibrahim, he worked as the General Manager of Roche Turkey. Dr. Taspolatoglu is a graduate of Ankara University Faculty of Medicine and served three years as a physician in the Ministry of Health.
Junge (John) Zhang, PhD
Dr. Junge (John) Zhang is the Founder, President, and CEO of Biopeptek, a company that specializes in the research and development of peptides. Since its founding in 2010, Dr. Zhang has established a company with over 50 experienced scientists and a state-of-the-art facility that is capable of producing high quality custom peptides for research and therapeutic uses. Through his many collaborations with major pharmaceutical companies and research institutions, Dr. Zhang is passionate about research to improve human health.
Prior to founding Biopeptek, Dr. Zhang was with the Janssen Pharmaceutical division of Johnson & Johnson. During his 9-year tenure at J&J, Dr. Zhang held numerous scientific and management positions and led multiple development projects related to three antibody drugs that received FDA approval. Prior to J&J, Dr. Zhang was a Senior Chemist at Eisai USA.
Dr. Zhang earned a Ph.D. in analytical chemistry from Drexel University, a M.S. in chemistry from University of Louisiana, and a B.S. in material science from Wuhan University of Technology in China. Dr. Zhang was born and raised in Qingdao China and immigrated to the United States to pursue his graduate education.